Status:
COMPLETED
Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma
Lead Sponsor:
Nantes University Hospital
Conditions:
Thyroid Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullar...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 18 -75 years
- Karnofsky ≥ 70%
- Histological diagnosis of medullary thyroid carcinoma
- Calcitonin serum level Ê 100 pg/ml and Calcitonin or CEA doubling time £ 5 years
- Normal liver and renal functions
- Granulocytes ≥ 1500/mm3 and platelets ≥ 150 000/mm3
- No immunization
- Consent form signed
Exclusion
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
End Date :
January 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00467506
Start Date
May 1 2004
End Date
January 1 2011
Last Update
November 11 2011
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre François Baclesse
Caen, France, 14076
2
CHU de Grenoble
Grenoble, France, 38043
3
hôpital du Cluzeau
Limoges, France, 87042
4
CHU
Lyon, France, 69394